Skip to content
Review Open access

Metabolic Pathways and Immune Interactions in Renal Cell Carcinoma

Nov 2026 · Cancers · Vol 18, pp. 3600 · 0 citations · 81 references

TL;DR

Renal cell carcinoma is increasingly recognized as a metabolic disease driven by genetic alterations that regulate cellular energetics, and recent advances in targeting these pathways are highlighted, alongside emerging metabolic biomarkers and imaging modalities.

Abstract

Renal cell carcinoma (RCC) is increasingly recognized as a metabolic disease driven by genetic alterations that regulate cellular energetics. In clear cell RCC (ccRCC), loss of the von Hippel-Lindau (VHL) gene stabilizes hypoxia-inducible factors (HIFs), promoting a pseudo-hypoxic state that enhances glycolysis, suppresses mitochondrial oxidation, and remodels lipid metabolism. Here we review how these metabolic reprogramming events, including glutamine dependence and oncometabolite accumulation in rarer subtypes, reshape the tumor microenvironment and contribute to immune evasion. We highlight recent advances in targeting these pathways, notably the clinical success of the HIF-2α inhibitor belzutifan, alongside emerging metabolic biomarkers and imaging modalities. These insights underscore the potential of metabolism-based strategies to improve RCC diagnosis and therapy while emphasizing the complex interplay between tumor metabolism and immune regulation.

Read PDF

Similar papers

Review Open access Sep 2026

Metabolic modulators as gatekeepers of immunotherapy response in colorectal cancer

Colorectal cancer (CRC) continues to pose a significant global health concern, largely driven by metabolic reprogramming mechanisms that facilitate tumor progression and enable immune evasion within the tumor microenvironment (TME). This review highlights the pivotal functions of dysregulated metabolic pathways, such...

Alireza Najafi, Ali Rahimi, Zeinab Baghernejadian et al. · 0 citations
Review Oct 2026

Hypoxia Signatures in Renal Cell Carcinoma: From HIF-Mediated Omics Remodeling to Precision Diagnostics.

Renal cell carcinoma (RCC), particularly clear cell RCC (ccRCC), exhibits extensive metabolic, signaling, and microenvironmental remodeling associated with dysregulated VHL-HIF signaling. HIF activation in RCC may arise from VHL loss under normoxic conditions and from genuine tumor hypoxia due to inadequate oxygen avai...

Malleshwari Mahalinga, A. Rai, T. Prasad · 0 citations
Review Open access Oct 2026

Mechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma

Renal cell carcinoma (RCC), particularly its clear-cell subtype (ccRCC), is characterized by metabolic reprogramming and a complex tumor microenvironment that influence responses to immune checkpoint inhibitors (ICIs). Despite clinical advances, therapeutic resistance remains a major hurdle. Here we review the molecula...

M. Milella, F. Lasorsa, M. Rutigliano et al. · 0 citations
#gene editing Review Open access Oct 2026

Mitochondrial Metabolic Reprogramming and Immune Evasion in Colorectal Cancer: Research Advances and Mechanistic Perspectives

Colorectal cancer (CRC) is one of the most prevalent malignancies of the gastrointestinal tract worldwide. Notably, most patients with microsatellite-stable (MSS) tumors show primary resistance to immune checkpoint inhibitors (ICIs), creating an unmet clinical need. The mechanisms underlying immune evasion and strategi...

Dai-Xun Ding, Jing-Yi Hu, Yi-Tong Wang et al. · 0 citations
Review Open access Nov 2026

Metabolic Reprogramming in Hepatocellular Carcinoma: Liver-Specific Immune Dysfunction, Immunotherapy Resistance, and Translational Biomarker Development.

Hepatocellular carcinoma (HCC) arises in chronically injured, often fibrotic or cirrhotic liver, where metabolism, immunity, vascular and stromal organization, disease etiology, tumor state, and hepatic reserve are tightly interconnected. Although immune checkpoint inhibitor (ICI)-based therapies have expanded treatmen...

Chun-Yan Dai, Shengying Lou, Hua-Li Luo et al. · 0 citations
Review Open access Oct 2026

Advancing osteosarcoma treatment: the impact of intratumoral metabolic reprogramming on immunotherapy

Osteosarcoma (OS) remains difficult to cure once it becomes metastatic, recurrent, or resistant to chemotherapy, and immune checkpoint blockade has provided limited clinical benefit. The metabolic-immune tumor microenvironment (TME) is one barrier to effective immunity because malignant, stromal, and immune cells compe...

Jia-Wei Yin, Shuai Lu, Yi-Kai Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.